The Relationship between Glaucoma Medication Adherence, Eye Drop Technique, and Visual Field Defect Severity
The purpose of the study was to examine (1) how patient adherence and eye drop technique were associated with visual field defect severity and (2) how general glaucoma adherence self-efficacy and eye drop technique self-efficacy were related to visual field defect severity. Cross-sectional study con...
Saved in:
Published in | Ophthalmology (Rochester, Minn.) Vol. 118; no. 12; pp. 2398 - 2402 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Elsevier Inc
01.12.2011
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The purpose of the study was to examine (1) how patient adherence and eye drop technique were associated with visual field defect severity and (2) how general glaucoma adherence self-efficacy and eye drop technique self-efficacy were related to visual field defect severity.
Cross-sectional study conducted at a single private practice site.
Patients using eye drops for their glaucoma.
Subject adherence to glaucoma medications through Medication Events Monitoring System (MEMS) devices were measured, and eye drop instillation technique was assessed by video recording. General glaucoma medication adherence self-efficacy was measured using a 10-item scale, and eye drop technique self-efficacy was measured using a 6-item scale. Multivariate logistic regression was used to analyze the data.
Visual field defect severity.
Patients who were less than 80% adherent according to the MEMS devices were significantly more likely to have worse defect severity. Patients with lower scores on the general glaucoma medication adherence self-efficacy scale also were significantly more likely to have worse defect severity. Eye drop technique and eye drop technique self-efficacy were not related significantly to visual field defect severity.
Eye care providers need to assess patient adherence and to work with those patients with poor adherence to find ways to improve their ability and self-efficacy in using their glaucoma medications.
Proprietary or commercial disclosure may be found after the references. |
---|---|
AbstractList | The purpose of the study was to examine (1) how patient adherence and eye drop technique were associated with visual field defect severity and (2) how general glaucoma adherence self-efficacy and eye drop technique self-efficacy were related to visual field defect severity.
Cross-sectional study conducted at a single private practice site.
Patients using eye drops for their glaucoma.
Subject adherence to glaucoma medications through Medication Events Monitoring System (MEMS) devices were measured, and eye drop instillation technique was assessed by video recording. General glaucoma medication adherence self-efficacy was measured using a 10-item scale, and eye drop technique self-efficacy was measured using a 6-item scale. Multivariate logistic regression was used to analyze the data.
Visual field defect severity.
Patients who were less than 80% adherent according to the MEMS devices were significantly more likely to have worse defect severity. Patients with lower scores on the general glaucoma medication adherence self-efficacy scale also were significantly more likely to have worse defect severity. Eye drop technique and eye drop technique self-efficacy were not related significantly to visual field defect severity.
Eye care providers need to assess patient adherence and to work with those patients with poor adherence to find ways to improve their ability and self-efficacy in using their glaucoma medications.
Proprietary or commercial disclosure may be found after the references. Objective The purpose of the study was to examine (1) how patient adherence and eye drop technique were associated with visual field defect severity and (2) how general glaucoma adherence self-efficacy and eye drop technique self-efficacy were related to visual field defect severity. Design Cross-sectional study conducted at a single private practice site. Participants Patients using eye drops for their glaucoma. Methods Subject adherence to glaucoma medications through Medication Events Monitoring System (MEMS) devices were measured, and eye drop instillation technique was assessed by video recording. General glaucoma medication adherence self-efficacy was measured using a 10-item scale, and eye drop technique self-efficacy was measured using a 6-item scale. Multivariate logistic regression was used to analyze the data. Main Outcome Measures Visual field defect severity. Results Patients who were less than 80% adherent according to the MEMS devices were significantly more likely to have worse defect severity. Patients with lower scores on the general glaucoma medication adherence self-efficacy scale also were significantly more likely to have worse defect severity. Eye drop technique and eye drop technique self-efficacy were not related significantly to visual field defect severity. Conclusions Eye care providers need to assess patient adherence and to work with those patients with poor adherence to find ways to improve their ability and self-efficacy in using their glaucoma medications. Financial Disclosure(s) Proprietary or commercial disclosure may be found after the references. The purpose of the study was to examine (1) how patient adherence and eye drop technique were associated with visual field defect severity and (2) how general glaucoma adherence self-efficacy and eye drop technique self-efficacy were related to visual field defect severity.OBJECTIVEThe purpose of the study was to examine (1) how patient adherence and eye drop technique were associated with visual field defect severity and (2) how general glaucoma adherence self-efficacy and eye drop technique self-efficacy were related to visual field defect severity.Cross-sectional study conducted at a single private practice site.DESIGNCross-sectional study conducted at a single private practice site.Patients using eye drops for their glaucoma.PARTICIPANTSPatients using eye drops for their glaucoma.Subject adherence to glaucoma medications through Medication Events Monitoring System (MEMS) devices were measured, and eye drop instillation technique was assessed by video recording. General glaucoma medication adherence self-efficacy was measured using a 10-item scale, and eye drop technique self-efficacy was measured using a 6-item scale. Multivariate logistic regression was used to analyze the data.METHODSSubject adherence to glaucoma medications through Medication Events Monitoring System (MEMS) devices were measured, and eye drop instillation technique was assessed by video recording. General glaucoma medication adherence self-efficacy was measured using a 10-item scale, and eye drop technique self-efficacy was measured using a 6-item scale. Multivariate logistic regression was used to analyze the data.Visual field defect severity.MAIN OUTCOME MEASURESVisual field defect severity.Patients who were less than 80% adherent according to the MEMS devices were significantly more likely to have worse defect severity. Patients with lower scores on the general glaucoma medication adherence self-efficacy scale also were significantly more likely to have worse defect severity. Eye drop technique and eye drop technique self-efficacy were not related significantly to visual field defect severity.RESULTSPatients who were less than 80% adherent according to the MEMS devices were significantly more likely to have worse defect severity. Patients with lower scores on the general glaucoma medication adherence self-efficacy scale also were significantly more likely to have worse defect severity. Eye drop technique and eye drop technique self-efficacy were not related significantly to visual field defect severity.Eye care providers need to assess patient adherence and to work with those patients with poor adherence to find ways to improve their ability and self-efficacy in using their glaucoma medications.CONCLUSIONSEye care providers need to assess patient adherence and to work with those patients with poor adherence to find ways to improve their ability and self-efficacy in using their glaucoma medications.Proprietary or commercial disclosure may be found after the references.FINANCIAL DISCLOSURE(S)Proprietary or commercial disclosure may be found after the references. |
Author | Stone, Jennifer L. Covert, David Muir, Kelly Robin, Alan L. Skinner, Asheley Cockrell Blalock, Susan Sleath, Betsy |
AuthorAffiliation | 2 Department of Health Economics, Alcon Research Ltd. Fort Worth, Texas 6 Department of International Health, Bloomberg School of Public Health; Department of Ophthalmology, School of Medicine; Johns Hopkins University and University of Maryland School of Medicine, Baltimore, Maryland 5 Department of Ophthalmology; School of Medicine, Duke University 3 Mid-Atlantic Glaucoma Experts, Baltimore, Maryland 4 Department of Pediatrics; Health Policy and Management; University of North Carolina at Chapel Hill 1 Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill |
AuthorAffiliation_xml | – name: 5 Department of Ophthalmology; School of Medicine, Duke University – name: 1 Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill – name: 6 Department of International Health, Bloomberg School of Public Health; Department of Ophthalmology, School of Medicine; Johns Hopkins University and University of Maryland School of Medicine, Baltimore, Maryland – name: 3 Mid-Atlantic Glaucoma Experts, Baltimore, Maryland – name: 2 Department of Health Economics, Alcon Research Ltd. Fort Worth, Texas – name: 4 Department of Pediatrics; Health Policy and Management; University of North Carolina at Chapel Hill |
Author_xml | – sequence: 1 givenname: Betsy surname: Sleath fullname: Sleath, Betsy email: betsy_sleath@unc.edu organization: Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina – sequence: 2 givenname: Susan surname: Blalock fullname: Blalock, Susan organization: Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina – sequence: 3 givenname: David surname: Covert fullname: Covert, David organization: Department of Health Economics, Alcon Research Ltd., Fort Worth, Texas – sequence: 4 givenname: Jennifer L. surname: Stone fullname: Stone, Jennifer L. organization: Mid-Atlantic Glaucoma Specialists, Baltimore, Maryland – sequence: 5 givenname: Asheley Cockrell surname: Skinner fullname: Skinner, Asheley Cockrell organization: Department of Pediatrics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina – sequence: 6 givenname: Kelly surname: Muir fullname: Muir, Kelly organization: Department of Ophthalmology, School of Medicine, Duke University, Durham, North Carolina – sequence: 7 givenname: Alan L. surname: Robin fullname: Robin, Alan L. organization: Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, and Department of Ophthalmology, School of Medicine, University of Maryland School of Medicine, Baltimore, Maryland |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25286153$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21856009$$D View this record in MEDLINE/PubMed |
BookMark | eNqVkl1rFDEUhoNU7Lb6D0RyI964azLJTGalCKVfChXBrt6GTHLGyZpN1mRmZf-9me5aP0CKV4HkOe8h5zlH6MAHDwg9pWRGCa1eLWdh3fWdmhWE0hkpZ4SyB2hCSz6fckHZAZpkjE4rXpBDdJTSkhBSVYw_QocFrcuKkPkEuUUH-CM41dvgU2fXuIH-O4DHV04NOqwUfg_G6tt3fGo6iOA1vMQXW8DnMazxAnTn7bch3ylv8GebBuXwpQVn8Dm0oHt8AxuItt8-Rg9b5RI82Z_H6NPlxeLs7fT6w9W7s9Prqa4K0k-FoUI0LafQGkLN3GhTN6pVDddG6JoKSoFVhJG6actWlKJgTdU0tWa60aVR7Bi92eWuh2YFRoPvo3JyHe1Kxa0Myso_X7zt5JewkawoWMnrHPBiHxBD_lnq5comDc4pD2FIck5qwangIpPPfm911-PnhDPwfA-opJVro_Lapl9cWdQVLVnm-I7TMaQUob1DKJGjcLmUO-FyFC5JKbPwXPb6rzJt-1tZ-WPW3Ve8nxNkGRsLUSZtR73GxuxNmmD_N0A76_O2uK-whbQMQ_RZtKQyFZLIm3Ehx32klBBeVuOgT_4dcH__H3S78_g |
CODEN | OPHTDG |
CitedBy_id | crossref_primary_10_1186_s12886_016_0220_6 crossref_primary_10_1080_17469899_2024_2382149 crossref_primary_10_1167_tvst_8_3_55 crossref_primary_10_1097_IJG_0000000000001728 crossref_primary_10_1007_s12325_023_02646_3 crossref_primary_10_1186_s12886_022_02361_7 crossref_primary_10_1001_jamaophthalmol_2021_4415 crossref_primary_10_1136_bmjophth_2017_000114 crossref_primary_10_2147_PPA_S239916 crossref_primary_10_1016_j_pec_2018_12_019 crossref_primary_10_1038_s41433_022_02277_y crossref_primary_10_1016_j_ogla_2023_07_002 crossref_primary_10_1038_s41433_023_02693_8 crossref_primary_10_1097_IJG_0000000000001965 crossref_primary_10_1097_OPX_0000000000000574 crossref_primary_10_5005_jp_journals_10008_1183 crossref_primary_10_1016_j_jfma_2018_07_011 crossref_primary_10_1089_jop_2012_0241 crossref_primary_10_1007_s00441_013_1672_0 crossref_primary_10_1146_annurev_vision_102016_061422 crossref_primary_10_1089_jop_2018_0067 crossref_primary_10_1021_acsbiomaterials_7b00319 crossref_primary_10_3390_jcm12093137 crossref_primary_10_1016_j_jfo_2016_02_004 crossref_primary_10_1007_s10792_022_02460_w crossref_primary_10_1097_IJG_0000000000002368 crossref_primary_10_2147_OPTH_S439457 crossref_primary_10_1016_j_ogla_2021_07_012 crossref_primary_10_1177_11206721241272179 crossref_primary_10_1097_ICU_0000000000000927 crossref_primary_10_1136_bjophthalmol_2021_320023 crossref_primary_10_1097_IJG_0000000000001716 crossref_primary_10_1080_17469899_2023_2199981 crossref_primary_10_5402_2012_902819 crossref_primary_10_3341_jkos_2023_64_1_43 crossref_primary_10_1007_s40123_019_0192_8 crossref_primary_10_3109_09273948_2014_902473 crossref_primary_10_4103_ijo_IJO_3333_20 crossref_primary_10_1080_17425255_2017_1277203 crossref_primary_10_1016_j_ophtha_2020_11_004 crossref_primary_10_2147_OPTH_S450220 crossref_primary_10_1186_1471_2415_12_57 crossref_primary_10_1177_2515841418812061 crossref_primary_10_1080_07853890_2021_1955146 crossref_primary_10_5005_jp_journals_10078_1283 crossref_primary_10_1016_j_ophtha_2019_04_034 crossref_primary_10_1007_s00417_021_05091_6 crossref_primary_10_1097_IJG_0000000000001982 crossref_primary_10_2147_OPTH_S420932 crossref_primary_10_1038_eye_2012_294 crossref_primary_10_1097_IJG_0000000000000777 crossref_primary_10_4103_jcsr_jcsr_174_23 crossref_primary_10_1007_s10597_016_0078_3 crossref_primary_10_1016_j_xops_2025_100706 crossref_primary_10_1016_j_ophtha_2024_03_012 crossref_primary_10_1097_IJG_0000000000001867 crossref_primary_10_1016_j_ogla_2022_08_001 crossref_primary_10_1111_aos_14776 crossref_primary_10_3341_jkos_2021_62_8_1105 crossref_primary_10_1007_s40265_019_01248_0 crossref_primary_10_1016_j_aopr_2024_09_002 crossref_primary_10_3390_app13137562 crossref_primary_10_3390_jcm5090079 crossref_primary_10_1016_j_xops_2024_100541 crossref_primary_10_3389_fopht_2023_1260415 crossref_primary_10_1016_j_ophtha_2016_06_038 crossref_primary_10_1016_j_ajo_2013_03_005 crossref_primary_10_1016_j_ogla_2021_04_007 crossref_primary_10_1111_ceo_13016 crossref_primary_10_1016_j_jfo_2022_07_025 crossref_primary_10_1007_s40123_021_00380_z crossref_primary_10_1371_journal_pone_0145764 crossref_primary_10_1186_s12951_023_01838_x crossref_primary_10_1097_IJG_0000000000001731 crossref_primary_10_1155_2017_1683430 crossref_primary_10_1016_j_ogla_2019_01_006 crossref_primary_10_2147_OPTH_S498431 crossref_primary_10_1016_j_jconrel_2017_11_008 crossref_primary_10_1016_j_clinthera_2015_06_008 crossref_primary_10_1016_j_ogla_2021_06_001 crossref_primary_10_1097_ICU_0000000000000031 crossref_primary_10_1371_journal_pone_0251699 crossref_primary_10_1016_j_ajo_2016_12_002 crossref_primary_10_1016_j_ophtha_2015_04_019 crossref_primary_10_1097_ICU_0000000000000953 crossref_primary_10_1097_IJG_0000000000000150 crossref_primary_10_1016_j_ajo_2020_09_008 crossref_primary_10_1016_j_ajo_2020_10_004 crossref_primary_10_1016_j_ajo_2024_12_015 crossref_primary_10_1021_acsomega_4c08540 crossref_primary_10_1080_09286586_2019_1708121 crossref_primary_10_1097_IJG_0000000000002213 crossref_primary_10_1038_eye_2013_187 crossref_primary_10_1089_jop_2015_0102 crossref_primary_10_3109_08820538_2013_771198 crossref_primary_10_3390_jcm13010184 crossref_primary_10_1016_j_ogla_2024_12_002 crossref_primary_10_1111_ceo_13156 crossref_primary_10_2147_OPTH_S445005 crossref_primary_10_1016_j_jcrs_2014_02_037 crossref_primary_10_1089_jop_2024_0029 crossref_primary_10_1016_j_ophtha_2015_06_039 crossref_primary_10_1007_s40123_022_00527_6 crossref_primary_10_1089_jop_2019_0146 crossref_primary_10_1016_j_ajo_2015_12_009 crossref_primary_10_3109_02713683_2013_855237 crossref_primary_10_1007_s40265_024_02074_9 crossref_primary_10_1097_IJG_0000000000002324 crossref_primary_10_2147_OPTH_S325763 crossref_primary_10_1097_APO_0000000000000023 crossref_primary_10_1097_APO_0000000000000025 crossref_primary_10_1016_j_preteyeres_2019_100801 crossref_primary_10_1093_her_cyv034 crossref_primary_10_1186_s40814_018_0320_6 crossref_primary_10_1016_j_ogla_2024_01_008 crossref_primary_10_1016_j_ogla_2020_04_013 crossref_primary_10_1016_j_ophtha_2012_11_026 crossref_primary_10_4103_tmj_tmj_16_23 crossref_primary_10_1016_j_ogla_2020_04_016 crossref_primary_10_1016_j_ajo_2018_01_011 crossref_primary_10_1155_2016_9183272 crossref_primary_10_3390_jcm12010151 crossref_primary_10_1177_1060028014529413 crossref_primary_10_1097_IJG_0000000000001943 crossref_primary_10_1097_OPX_0000000000001366 crossref_primary_10_2147_OPTH_S278627 crossref_primary_10_1016_j_ajo_2022_08_011 crossref_primary_10_1080_14656566_2020_1795130 crossref_primary_10_1097_IJG_0000000000001824 crossref_primary_10_1136_bmjophth_2023_001607 crossref_primary_10_1016_j_ijpharm_2019_01_070 crossref_primary_10_1016_j_evalprogplan_2017_06_006 crossref_primary_10_1016_j_biomaterials_2013_09_032 crossref_primary_10_1186_s12886_016_0316_z crossref_primary_10_1177_2515841419863638 crossref_primary_10_1016_j_ogla_2024_12_008 crossref_primary_10_1016_j_ogla_2020_08_003 crossref_primary_10_1007_s40135_021_00273_1 crossref_primary_10_1080_08820538_2021_1985145 crossref_primary_10_1016_j_ogla_2023_04_004 crossref_primary_10_23736_S0026_4946_16_04731_9 crossref_primary_10_1007_s10792_021_02085_5 crossref_primary_10_1080_00981389_2019_1614711 crossref_primary_10_5005_jp_journals_10008_1139 crossref_primary_10_1097_IJG_0000000000002343 crossref_primary_10_1097_IJG_0000000000002228 crossref_primary_10_3390_s20092570 crossref_primary_10_1016_j_clae_2015_02_001 crossref_primary_10_1007_s40123_024_01041_7 crossref_primary_10_1016_j_ogla_2023_05_001 crossref_primary_10_1038_s41433_020_0798_z crossref_primary_10_1155_joph_9803788 crossref_primary_10_3390_ijms242115599 crossref_primary_10_2147_OPTH_S335764 crossref_primary_10_1016_j_ajo_2020_01_004 crossref_primary_10_18553_jmcp_2018_17465 crossref_primary_10_15275_rusomj_2022_0407 crossref_primary_10_1016_j_exer_2022_109006 crossref_primary_10_1097_OPX_0000000000000856 crossref_primary_10_3390_jcm12083031 crossref_primary_10_1155_2023_5625990 crossref_primary_10_2147_OPTH_S321351 crossref_primary_10_1080_14740338_2020_1826928 crossref_primary_10_1080_10410236_2015_1020263 crossref_primary_10_3109_02713683_2014_1002045 crossref_primary_10_1016_j_ophtha_2013_01_002 crossref_primary_10_2147_OPTH_S440840 crossref_primary_10_1007_s40123_023_00804_y crossref_primary_10_3390_healthcare11050635 crossref_primary_10_1016_j_ogla_2024_11_003 crossref_primary_10_1016_j_pec_2015_07_001 crossref_primary_10_1185_03007995_2013_815159 crossref_primary_10_54133_ajms_v7i2_1283 crossref_primary_10_1016_j_ophtha_2014_11_001 crossref_primary_10_1097_j_jcrs_0000000000001537 crossref_primary_10_1177_25158414211045751 crossref_primary_10_3389_fmed_2022_867884 crossref_primary_10_1016_j_jconrel_2015_06_035 crossref_primary_10_1016_j_jaapos_2024_103963 crossref_primary_10_1371_journal_pone_0316835 crossref_primary_10_1089_tmj_2016_0254 crossref_primary_10_1097_IJG_0000000000000342 crossref_primary_10_1097_IJG_0000000000000345 crossref_primary_10_1016_j_ogla_2025_01_008 crossref_primary_10_7759_cureus_15545 crossref_primary_10_1016_j_ogla_2023_01_006 crossref_primary_10_1089_jop_2015_0052 crossref_primary_10_1080_17434440_2018_1419060 crossref_primary_10_21516_2072_0076_2024_17_2_121_127 crossref_primary_10_1080_02713683_2019_1625405 crossref_primary_10_3390_gels8080510 crossref_primary_10_1186_1471_2415_14_79 crossref_primary_10_1136_bjophthalmol_2021_319786 crossref_primary_10_1097_IJG_0000000000000380 crossref_primary_10_1038_s41433_023_02674_x crossref_primary_10_53394_akd_1057689 crossref_primary_10_1016_j_ophtha_2019_10_022 crossref_primary_10_1038_s41433_019_0665_y crossref_primary_10_1080_03007995_2024_2322048 crossref_primary_10_1080_13696998_2019_1646262 crossref_primary_10_1038_s41598_017_15954_w crossref_primary_10_1371_journal_pone_0293047 crossref_primary_10_1097_ICU_0000000000001077 crossref_primary_10_1111_cxo_12372 crossref_primary_10_1089_tmj_2017_0324 crossref_primary_10_1007_s40265_023_01973_7 crossref_primary_10_3390_ijms24065636 crossref_primary_10_1038_s41551_020_00645_1 crossref_primary_10_1097_OPX_0000000000001959 crossref_primary_10_2147_PPA_S264926 crossref_primary_10_1111_ijpp_12215 crossref_primary_10_18502_jovr_v19i2_13983 crossref_primary_10_1111_vop_13029 crossref_primary_10_1001_jamaophthalmol_2022_0055 crossref_primary_10_1159_000512924 crossref_primary_10_1007_s00347_012_2641_9 crossref_primary_10_1007_s40123_023_00831_9 crossref_primary_10_3390_app15031627 crossref_primary_10_1080_03007995_2024_2323644 crossref_primary_10_1016_j_yaoo_2021_04_011 crossref_primary_10_1016_j_ogla_2023_06_002 crossref_primary_10_1007_s12160_014_9641_8 crossref_primary_10_1002_14651858_CD010520_pub2 crossref_primary_10_1016_j_ajo_2020_02_009 crossref_primary_10_1097_ICU_0000000000000555 crossref_primary_10_1016_j_jcjo_2021_01_008 crossref_primary_10_1097_IJG_0000000000000431 crossref_primary_10_1007_s40265_021_01624_9 crossref_primary_10_1016_j_ophtha_2016_04_026 crossref_primary_10_1097_OPX_0000000000001173 crossref_primary_10_1007_s40266_015_0282_9 crossref_primary_10_1016_j_jcrs_2018_07_015 crossref_primary_10_1097_IJG_0000000000002166 crossref_primary_10_1371_journal_pone_0312390 crossref_primary_10_1155_2015_234157 crossref_primary_10_1097_j_jcrs_0000000000000363 crossref_primary_10_1139_cjc_2017_0193 crossref_primary_10_1089_jop_2013_0229 crossref_primary_10_1136_bjophthalmol_2020_317918 crossref_primary_10_3390_pharmaceutics16070933 crossref_primary_10_1097_ICU_0000000000000451 crossref_primary_10_1186_1471_2415_14_32 crossref_primary_10_1016_j_ophtha_2020_06_018 crossref_primary_10_1080_09286586_2022_2078495 crossref_primary_10_1007_s00441_013_1637_3 crossref_primary_10_1097_IJG_0000000000000332 crossref_primary_10_4103_IJO_IJO_2186_23 crossref_primary_10_18553_jmcp_2016_22_7_808 crossref_primary_10_1016_j_pec_2023_107679 crossref_primary_10_1080_10410236_2014_888387 crossref_primary_10_1007_s40123_019_00214_z crossref_primary_10_1016_j_jcjo_2014_04_012 crossref_primary_10_1016_j_ajo_2016_11_020 crossref_primary_10_1177_25158414241287431 crossref_primary_10_1016_j_ajo_2015_03_006 crossref_primary_10_1016_j_ajo_2017_07_023 crossref_primary_10_1097_IIO_0000000000000441 crossref_primary_10_2147_OPTH_S452159 crossref_primary_10_18553_jmcp_2019_25_9_1001 crossref_primary_10_1097_IJG_0000000000001891 crossref_primary_10_1016_j_ogla_2022_09_003 crossref_primary_10_1097_IJG_0000000000000320 crossref_primary_10_1136_bmjopen_2020_039788 crossref_primary_10_1016_j_xops_2025_100758 crossref_primary_10_1016_j_ophtha_2015_03_026 crossref_primary_10_1007_s40123_024_01087_7 crossref_primary_10_1080_17469899_2019_1635456 crossref_primary_10_1177_17407745221136571 |
Cites_doi | 10.1016/j.ophtha.2008.09.004 10.1016/j.amjopharm.2009.04.001 10.1038/eye.2000.197 10.1136/bjo.64.2.137 10.1016/j.ophtha.2005.10.034 10.1136/bjo.87.5.648 10.1016/j.ophtha.2004.12.035 10.1016/j.ophtha.2009.01.021 10.1097/00061198-200310000-00001 10.1001/archophthalmol.2009.96 10.1097/00005650-199808000-00004 10.1016/S0002-9394(14)74225-4 10.1016/j.ajo.2010.05.005 10.1016/j.ajo.2006.03.018 10.1038/eye.2009.174 10.1016/j.ophtha.2004.12.026 10.1097/IJG.0b013e31819c4679 10.1345/aph.1K671 10.1016/j.ajo.2007.06.012 10.1089/10807680260362687 10.1097/01.mlr.0000114908.90348.f9 |
ContentType | Journal Article |
Copyright | 2011 American Academy of Ophthalmology American Academy of Ophthalmology 2015 INIST-CNRS Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. 2011 American Academy of Ophthalmology, Inc. Published by Elsevier Inc. All rights reserved. 2011 |
Copyright_xml | – notice: 2011 American Academy of Ophthalmology – notice: American Academy of Ophthalmology – notice: 2015 INIST-CNRS – notice: Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. – notice: 2011 American Academy of Ophthalmology, Inc. Published by Elsevier Inc. All rights reserved. 2011 |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1016/j.ophtha.2011.05.013 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1549-4713 |
EndPage | 2402 |
ExternalDocumentID | PMC3223548 21856009 25286153 10_1016_j_ophtha_2011_05_013 S0161642011004568 1_s2_0_S0161642011004568 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: National Institutes of Health grantid: EY018400 – fundername: National Center of Research Resources, National Institutes of Health grantid: 1RR02574 7 – fundername: NCRR NIH HHS grantid: UL1RR02574 7 – fundername: NEI NIH HHS grantid: EY018400 – fundername: NEI NIH HHS grantid: R01 EY018400 – fundername: National Eye Institute : NEI grantid: R01 EY018400-03 || EY |
GroupedDBID | --- --K .1- .55 .FO .GJ 0R~ 123 1B1 1CY 1P~ 1~5 29N 4.4 457 4G. 53G 5RE 5VS 7-5 71M AAEDT AAEDW AALRI AAQFI AAQQT AAQXK AAXUO ABCQX ABFRF ABJNI ABLJU ABMAC ABOCM ABWVN ACGFO ACGFS ACIUM ACNCT ACRPL ACVFH ADCNI ADMUD ADNMO AEFWE AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AGCQF AGQPQ AIGII AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BELOY C5W CS3 DU5 EBS EFJIC EFKBS EJD F5P FDB FEDTE FGOYB GBLVA HVGLF HZ~ IHE J1W K-O KOM L7B M27 M41 MO0 N4W N9A NQ- O9- OF- OPF OQ~ P2P R2- ROL RPZ SDG SEL SES SSZ UHS UNMZH UV1 WH7 X7M XH2 XPP Z5R ZGI ZXP ADPAM RIG AAIAV AGZHU AHPSJ ALXNB ZA5 AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c620t-7d177bf41efd01d9dcd8bafab4cd7c81711e360308bf5f75723b6bb8c3cbc5da3 |
ISSN | 0161-6420 1549-4713 |
IngestDate | Thu Aug 21 18:27:28 EDT 2025 Fri Jul 11 00:46:19 EDT 2025 Sat May 31 02:07:38 EDT 2025 Mon Jul 21 09:10:50 EDT 2025 Thu Apr 24 23:08:15 EDT 2025 Tue Jul 01 01:01:32 EDT 2025 Fri Feb 23 02:14:12 EST 2024 Sun Feb 23 10:19:56 EST 2025 Tue Aug 26 19:02:59 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | Eye drop Drug Eye disease Chemotherapy Treatment Visual field disease Glaucoma (eye) Visual field defect Ophthalmology Technique Adhesion |
Language | English |
License | CC BY 4.0 Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c620t-7d177bf41efd01d9dcd8bafab4cd7c81711e360308bf5f75723b6bb8c3cbc5da3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 21856009 |
PQID | 908741747 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3223548 proquest_miscellaneous_908741747 pubmed_primary_21856009 pascalfrancis_primary_25286153 crossref_primary_10_1016_j_ophtha_2011_05_013 crossref_citationtrail_10_1016_j_ophtha_2011_05_013 elsevier_sciencedirect_doi_10_1016_j_ophtha_2011_05_013 elsevier_clinicalkeyesjournals_1_s2_0_S0161642011004568 elsevier_clinicalkey_doi_10_1016_j_ophtha_2011_05_013 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2011-12-01 |
PublicationDateYYYYMMDD | 2011-12-01 |
PublicationDate_xml | – month: 12 year: 2011 text: 2011-12-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | New York, NY |
PublicationPlace_xml | – name: New York, NY – name: United States |
PublicationTitle | Ophthalmology (Rochester, Minn.) |
PublicationTitleAlternate | Ophthalmology |
PublicationYear | 2011 |
Publisher | Elsevier Inc Elsevier |
Publisher_xml | – name: Elsevier Inc – name: Elsevier |
References | Tsai, McClure, Ramos (bib13) 2003; 12 Meichenbaum, Turk (bib15) 1987 Konstas, Maskaleris, Gratsonidis, Sardelli (bib19) 2000; 14 Robin, Covert (bib12) 2005; 112 Stryker, Beck, Primo (bib6) 2010; 19 Hodapp, Parrish, Anderson (bib26) 1993 Martin, Wiley-Exley, Richards (bib27) 2009; 41 Friedman, Okeke, Jampel (bib21) 2009; 116 Robin, Novack, Covert (bib11) 2007; 144 Stone, Robin, Novack (bib23) 2009; 127 Patel, Spaeth (bib28) 1995; 26 DiMatteo (bib17) 2004; 42 Sleath, Robin, Covert (bib9) 2006; 113 Sleath, Ballinger, Covert (bib7) 2009; 7 Taylor, Galbraith, Mills (bib14) 2002; 18 Spaeth (bib1) 1970; 9 Olthoff, Schouten, van de Borne, Webers (bib18) 2005; 112 Okeke, Quigley, Jampel (bib4) 2009; 116 Lu, Goldberg, Lu (bib5) 2010; 150 Rossi, Pasinetti, Scudeller (bib22) 2010 Dec 3 Kass, Hodapp, Gordon (bib3) 1982; 14 Sleath, Blalock, Robin (bib8) 2010; 24 Kass, Gordon, Morley (bib24) 1987; 103 Roter, Hall, Merisca (bib16) 1998; 36 Chen, Chao, Sorkin (bib20) 2003; 87 Sleath, Blalock, Stone (bib25) 2011 May 24 Muir, Santiago-Turla, Stinnett (bib10) 2006; 142 Norell, Granstrom (bib2) 1980; 64 Sleath (10.1016/j.ophtha.2011.05.013_bib8) 2010; 24 Stryker (10.1016/j.ophtha.2011.05.013_bib6) 2010; 19 Muir (10.1016/j.ophtha.2011.05.013_bib10) 2006; 142 Sleath (10.1016/j.ophtha.2011.05.013_bib7) 2009; 7 Patel (10.1016/j.ophtha.2011.05.013_bib28) 1995; 26 Lu (10.1016/j.ophtha.2011.05.013_bib5) 2010; 150 Robin (10.1016/j.ophtha.2011.05.013_bib11) 2007; 144 Robin (10.1016/j.ophtha.2011.05.013_bib12) 2005; 112 Spaeth (10.1016/j.ophtha.2011.05.013_bib1) 1970; 9 DiMatteo (10.1016/j.ophtha.2011.05.013_bib17) 2004; 42 Chen (10.1016/j.ophtha.2011.05.013_bib20) 2003; 87 Sleath (10.1016/j.ophtha.2011.05.013_bib9) 2006; 113 Friedman (10.1016/j.ophtha.2011.05.013_bib21) 2009; 116 Tsai (10.1016/j.ophtha.2011.05.013_bib13) 2003; 12 Taylor (10.1016/j.ophtha.2011.05.013_bib14) 2002; 18 Stone (10.1016/j.ophtha.2011.05.013_bib23) 2009; 127 Kass (10.1016/j.ophtha.2011.05.013_bib24) 1987; 103 Kass (10.1016/j.ophtha.2011.05.013_bib3) 1982; 14 Roter (10.1016/j.ophtha.2011.05.013_bib16) 1998; 36 Okeke (10.1016/j.ophtha.2011.05.013_bib4) 2009; 116 Olthoff (10.1016/j.ophtha.2011.05.013_bib18) 2005; 112 Konstas (10.1016/j.ophtha.2011.05.013_bib19) 2000; 14 Meichenbaum (10.1016/j.ophtha.2011.05.013_bib15) 1987 Martin (10.1016/j.ophtha.2011.05.013_bib27) 2009; 41 Hodapp (10.1016/j.ophtha.2011.05.013_bib26) 1993 Norell (10.1016/j.ophtha.2011.05.013_bib2) 1980; 64 Rossi (10.1016/j.ophtha.2011.05.013_bib22) 2010 Sleath (10.1016/j.ophtha.2011.05.013_bib25) 2011 |
References_xml | – volume: 142 start-page: 223 year: 2006 end-page: 226 ident: bib10 article-title: Health literacy and adherence to glaucoma therapy publication-title: Am J Ophthalmol – volume: 12 start-page: 393 year: 2003 end-page: 398 ident: bib13 article-title: Compliance barriers in glaucoma: a systematic classification publication-title: J Glaucoma – volume: 103 start-page: 188 year: 1987 end-page: 193 ident: bib24 article-title: Compliance with topical timolol treatment publication-title: Am J Ophthalmol – start-page: 1 year: 1987 end-page: 55 ident: bib15 article-title: Facilitating Treatment Adherence publication-title: A Practitioner's Guidebook – volume: 9 start-page: 73 year: 1970 end-page: 82 ident: bib1 article-title: Visual loss in a glaucoma clinic. I. Sociological considerations publication-title: Invest Ophthalmol – volume: 26 start-page: 233 year: 1995 end-page: 236 ident: bib28 article-title: Compliance in patients prescribed eye drops for glaucoma publication-title: Ophthalmic Surg – volume: 7 start-page: 67 year: 2009 end-page: 73 ident: bib7 article-title: Self-report prevalence and factors associated with nonadherence with glaucoma medications in veteran outpatients publication-title: Am J Geriatr Pharmacother – volume: 42 start-page: 200 year: 2004 end-page: 209 ident: bib17 article-title: Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research publication-title: Med Care – volume: 14 start-page: 752 year: 2000 end-page: 756 ident: bib19 article-title: Compliance and viewpoint of glaucoma patients in Greece publication-title: Eye (Lond) – volume: 64 start-page: 137 year: 1980 end-page: 141 ident: bib2 article-title: Self-medication with pilocarpine among outpatients in a glaucoma clinic publication-title: Br J Ophthalmol – volume: 19 start-page: 66 year: 2010 end-page: 72 ident: bib6 article-title: An exploratory study of factors influencing glaucoma treatment adherence publication-title: J Glaucoma – volume: 112 start-page: 863 year: 2005 end-page: 868 ident: bib12 article-title: Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? publication-title: Ophthalmology – start-page: 53 year: 1993 end-page: 59 ident: bib26 article-title: Clinical Decisions in Glaucoma – volume: 116 start-page: 191 year: 2009 end-page: 199 ident: bib4 article-title: Adherence with topical glaucoma medication monitored electronically: the Travatan Dosing Aid study publication-title: Ophthalmology – year: 2011 May 24 ident: bib25 article-title: Validation of a short version of the Glaucoma Medication Self-Efficacy Questionnaire publication-title: Br J Ophthalmol – volume: 150 start-page: 569 year: 2010 end-page: 574 ident: bib5 article-title: Use of glaucoma medications: state of the science and directions for observational research publication-title: Am J Ophthalmol – volume: 112 start-page: 953 year: 2005 end-page: 961 ident: bib18 article-title: Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review publication-title: Ophthalmology – volume: 144 start-page: 533 year: 2007 end-page: 540 ident: bib11 article-title: Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use publication-title: Am J Ophthalmol – year: 2010 Dec 3 ident: bib22 article-title: Do adherence rates and glaucomatous visual field progression correlate? publication-title: Eur J Ophthalmol – volume: 87 start-page: 648 year: 2003 end-page: 649 ident: bib20 article-title: Topiramate induced myopic shift and angle closure glaucoma [letter] publication-title: Br J Ophthalmol – volume: 18 start-page: 401 year: 2002 end-page: 409 ident: bib14 article-title: Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study publication-title: J Ocul Pharmacol Ther – volume: 116 start-page: 1097 year: 2009 end-page: 1105 ident: bib21 article-title: Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma publication-title: Ophthalmology – volume: 24 start-page: 624 year: 2010 end-page: 631 ident: bib8 article-title: Development of an instrument to measure glaucoma medication self-efficacy and outcome expectations publication-title: Eye (Lond) – volume: 113 start-page: 421 year: 2006 end-page: 426 ident: bib9 article-title: Patient-reported behavior and problems in using glaucoma medications publication-title: Ophthalmology – volume: 36 start-page: 1138 year: 1998 end-page: 1161 ident: bib16 article-title: Effectiveness of interventions to improve patient compliance: a meta-analysis publication-title: Med Care – volume: 14 start-page: 775 year: 1982 end-page: 779 ident: bib3 article-title: Part I. Patient administration of eyedrops: interview publication-title: Ann Ophthalmol – volume: 127 start-page: 732 year: 2009 end-page: 736 ident: bib23 article-title: An objective evaluation of eyedrop instillation in subjects with glaucoma publication-title: Arch Ophthalmol – volume: 41 start-page: 36 year: 2009 end-page: 44 ident: bib27 article-title: Contrasting measures of adherence in the presence of simple drug use, medication switching, and therapeutic duplication publication-title: Ann Pharmacother – volume: 116 start-page: 191 year: 2009 ident: 10.1016/j.ophtha.2011.05.013_bib4 article-title: Adherence with topical glaucoma medication monitored electronically: the Travatan Dosing Aid study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2008.09.004 – volume: 7 start-page: 67 year: 2009 ident: 10.1016/j.ophtha.2011.05.013_bib7 article-title: Self-report prevalence and factors associated with nonadherence with glaucoma medications in veteran outpatients publication-title: Am J Geriatr Pharmacother doi: 10.1016/j.amjopharm.2009.04.001 – volume: 14 start-page: 752 year: 2000 ident: 10.1016/j.ophtha.2011.05.013_bib19 article-title: Compliance and viewpoint of glaucoma patients in Greece publication-title: Eye (Lond) doi: 10.1038/eye.2000.197 – volume: 64 start-page: 137 year: 1980 ident: 10.1016/j.ophtha.2011.05.013_bib2 article-title: Self-medication with pilocarpine among outpatients in a glaucoma clinic publication-title: Br J Ophthalmol doi: 10.1136/bjo.64.2.137 – volume: 113 start-page: 421 year: 2006 ident: 10.1016/j.ophtha.2011.05.013_bib9 article-title: Patient-reported behavior and problems in using glaucoma medications publication-title: Ophthalmology doi: 10.1016/j.ophtha.2005.10.034 – volume: 87 start-page: 648 year: 2003 ident: 10.1016/j.ophtha.2011.05.013_bib20 article-title: Topiramate induced myopic shift and angle closure glaucoma [letter] publication-title: Br J Ophthalmol doi: 10.1136/bjo.87.5.648 – start-page: 53 year: 1993 ident: 10.1016/j.ophtha.2011.05.013_bib26 article-title: Clinical Decisions in Glaucoma – volume: 14 start-page: 775 year: 1982 ident: 10.1016/j.ophtha.2011.05.013_bib3 article-title: Part I. Patient administration of eyedrops: interview publication-title: Ann Ophthalmol – volume: 112 start-page: 953 year: 2005 ident: 10.1016/j.ophtha.2011.05.013_bib18 article-title: Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review publication-title: Ophthalmology doi: 10.1016/j.ophtha.2004.12.035 – volume: 116 start-page: 1097 year: 2009 ident: 10.1016/j.ophtha.2011.05.013_bib21 article-title: Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma publication-title: Ophthalmology doi: 10.1016/j.ophtha.2009.01.021 – volume: 12 start-page: 393 year: 2003 ident: 10.1016/j.ophtha.2011.05.013_bib13 article-title: Compliance barriers in glaucoma: a systematic classification publication-title: J Glaucoma doi: 10.1097/00061198-200310000-00001 – volume: 127 start-page: 732 year: 2009 ident: 10.1016/j.ophtha.2011.05.013_bib23 article-title: An objective evaluation of eyedrop instillation in subjects with glaucoma publication-title: Arch Ophthalmol doi: 10.1001/archophthalmol.2009.96 – volume: 9 start-page: 73 year: 1970 ident: 10.1016/j.ophtha.2011.05.013_bib1 article-title: Visual loss in a glaucoma clinic. I. Sociological considerations publication-title: Invest Ophthalmol – volume: 36 start-page: 1138 year: 1998 ident: 10.1016/j.ophtha.2011.05.013_bib16 article-title: Effectiveness of interventions to improve patient compliance: a meta-analysis publication-title: Med Care doi: 10.1097/00005650-199808000-00004 – volume: 103 start-page: 188 year: 1987 ident: 10.1016/j.ophtha.2011.05.013_bib24 article-title: Compliance with topical timolol treatment publication-title: Am J Ophthalmol doi: 10.1016/S0002-9394(14)74225-4 – volume: 150 start-page: 569 year: 2010 ident: 10.1016/j.ophtha.2011.05.013_bib5 article-title: Use of glaucoma medications: state of the science and directions for observational research publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2010.05.005 – volume: 142 start-page: 223 year: 2006 ident: 10.1016/j.ophtha.2011.05.013_bib10 article-title: Health literacy and adherence to glaucoma therapy publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2006.03.018 – volume: 24 start-page: 624 year: 2010 ident: 10.1016/j.ophtha.2011.05.013_bib8 article-title: Development of an instrument to measure glaucoma medication self-efficacy and outcome expectations publication-title: Eye (Lond) doi: 10.1038/eye.2009.174 – volume: 26 start-page: 233 year: 1995 ident: 10.1016/j.ophtha.2011.05.013_bib28 article-title: Compliance in patients prescribed eye drops for glaucoma publication-title: Ophthalmic Surg – year: 2010 ident: 10.1016/j.ophtha.2011.05.013_bib22 article-title: Do adherence rates and glaucomatous visual field progression correlate? publication-title: Eur J Ophthalmol – year: 2011 ident: 10.1016/j.ophtha.2011.05.013_bib25 article-title: Validation of a short version of the Glaucoma Medication Self-Efficacy Questionnaire publication-title: Br J Ophthalmol – volume: 112 start-page: 863 year: 2005 ident: 10.1016/j.ophtha.2011.05.013_bib12 article-title: Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? publication-title: Ophthalmology doi: 10.1016/j.ophtha.2004.12.026 – volume: 19 start-page: 66 year: 2010 ident: 10.1016/j.ophtha.2011.05.013_bib6 article-title: An exploratory study of factors influencing glaucoma treatment adherence publication-title: J Glaucoma doi: 10.1097/IJG.0b013e31819c4679 – volume: 41 start-page: 36 year: 2009 ident: 10.1016/j.ophtha.2011.05.013_bib27 article-title: Contrasting measures of adherence in the presence of simple drug use, medication switching, and therapeutic duplication publication-title: Ann Pharmacother doi: 10.1345/aph.1K671 – volume: 144 start-page: 533 year: 2007 ident: 10.1016/j.ophtha.2011.05.013_bib11 article-title: Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2007.06.012 – start-page: 1 year: 1987 ident: 10.1016/j.ophtha.2011.05.013_bib15 article-title: Facilitating Treatment Adherence – volume: 18 start-page: 401 year: 2002 ident: 10.1016/j.ophtha.2011.05.013_bib14 article-title: Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study publication-title: J Ocul Pharmacol Ther doi: 10.1089/10807680260362687 – volume: 42 start-page: 200 year: 2004 ident: 10.1016/j.ophtha.2011.05.013_bib17 article-title: Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research publication-title: Med Care doi: 10.1097/01.mlr.0000114908.90348.f9 |
SSID | ssj0006634 |
Score | 2.5106504 |
Snippet | The purpose of the study was to examine (1) how patient adherence and eye drop technique were associated with visual field defect severity and (2) how general... Objective The purpose of the study was to examine (1) how patient adherence and eye drop technique were associated with visual field defect severity and (2)... |
SourceID | pubmedcentral proquest pubmed pascalfrancis crossref elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2398 |
SubjectTerms | Administration, Ophthalmic Adult Aged Aged, 80 and over Antihypertensive Agents - administration & dosage Biological and medical sciences Cross-Sectional Studies Diseases of visual field, optic nerve, optic chiasma and optic tracts Female Glaucoma - drug therapy Glaucoma - ethnology Glaucoma and intraocular pressure Humans Male Medical sciences Medication Adherence Middle Aged Miscellaneous Ophthalmic Solutions - administration & dosage Ophthalmology Self Administration Severity of Illness Index Surveys and Questionnaires Treatment Outcome Vision Disorders - physiopathology Visual Acuity - physiology Visual Field Tests Visual Fields - physiology |
Title | The Relationship between Glaucoma Medication Adherence, Eye Drop Technique, and Visual Field Defect Severity |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0161642011004568 https://www.clinicalkey.es/playcontent/1-s2.0-S0161642011004568 https://dx.doi.org/10.1016/j.ophtha.2011.05.013 https://www.ncbi.nlm.nih.gov/pubmed/21856009 https://www.proquest.com/docview/908741747 https://pubmed.ncbi.nlm.nih.gov/PMC3223548 |
Volume | 118 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZKJyEkhLiOcpn8wNuWKnEudh6rwZgYA4ltsDcrthO1U0irJX2A38KP5Th2blvRxl6iKo1r1-fL8Tn2d85B6B0ThMZulDixBBUYuFngCFe4jpCBkkyJgCgdnHz8JTo8Cz6dh-ej0Z8ea2ldian8vTGu5C5ShXsgVx0l-x-SbX8UbsBnkC9cQcJwvbWMWzZbn3X1MU_W0GFiz2FqGc_U3IT21ervV7r7_nK5MlvrOodrQ-P8vih1RMmBZraBNqpzG5-kMDWLanAC_HU1r-ZJ_tPkcKo3ImztLcPGL4ppb5fhJNemZg2mtCq7IIo8ya1CHtCD9jWxtLrCua9rupkN2IaTs_t52t-20Ly5AQWkjacZ0D21_emAR-QO9HOnoNct6dqqW9-UsLZLtz4p2rgsmB2Ki-mynhqbuFXna_W7ZbAlJ57oUehB1Nn0wojdQ1sEnBAyRluzo28_jtqVHqw1mzvejLoJzaz5g9f7-pfp83CVlPBCZqaSyiZX5ypjt2cCnT5Gj6zvgmcGiE_QKC2eovvHlp3xDOWAR9zHI7Z4xA0ecYdH3OJxDwMasUYjbtG4hwGL2GAR11jEBou4weJzdHbw4XT_0LHVPBwZEbdyqPIoFVngpZlyPRUrqZhIskQEUlHJPOp5qR_p9EkiCzMaUuKLSAgmfSlkqBL_BRoXgLKXCIcxcWOWpr4pj-AxJSMGhmhGPclCIibIbyaaS5vqXldcyXnDabzgRjxci4e7IQfxTJDTtlqZVC83PB82MuRNGDMsvBxAd0M7uqldWlrNUnKPl4S7_BoQ-y2tgWwM31v0uTMAWfsHSUiY9vkmCDeo47DA6FPDpEiX65LHLgOvgwZ0grYNCLvGYOyDwxTDuAbwbB_QueuH3xSLeZ3DHuwIPwzYqzvO4Wv0oFMqb9C4ulynb8E7qMSOfUn_AiXvEgE |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Relationship+between+Glaucoma+Medication+Adherence%2C+Eye+Drop+Technique%2C+and+Visual+Field+Defect+Severity&rft.jtitle=Ophthalmology+%28Rochester%2C+Minn.%29&rft.au=Sleath%2C+Betsy&rft.au=Blalock%2C+Susan&rft.au=Covert%2C+David&rft.au=Stone%2C+Jennifer+L.&rft.date=2011-12-01&rft.pub=Elsevier+Inc&rft.issn=0161-6420&rft.volume=118&rft.issue=12&rft.spage=2398&rft.epage=2402&rft_id=info:doi/10.1016%2Fj.ophtha.2011.05.013&rft.externalDocID=S0161642011004568 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01616420%2FS0161642011X00118%2Fcov150h.gif |